Precision oncology and diagnostics receive significant enhancements through multiomics technologies and liquid biopsy platforms. Personalis and Yale launched a clinical trial evaluating ctDNA-guided breast cancer treatment to personalize adjuvant therapies. Exact Sciences debuted Cancerguard, a liquid biopsy test capable of detecting over 50 cancer types, with broad patient accessibility in the U.S. Meanwhile, Ignite Proteomics partnered with Inova Health to apply reverse phase protein array technology for late-stage gastrointestinal cancer profiling. These initiatives collectively foster personalized, earlier detection and tailored treatment strategies across oncology.